Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

  • Hamilton R
  • Banez L
  • Aronson W
 et al. 
  • 31


    Mendeley users who have this article in their library.
  • 87


    Citations of this article.


BACKGROUND: Although controversial, evidence suggests statins may reduce the risk of advanced prostate cancer (PC), and recently statin use was associated with prostate-specific antigen (PSA) reductions among men without PC. The authors sought to examine the association between statin use and PSA recurrence after radical prostatectomy (RP).

METHODS: The authors examined 1319 men treated with RP from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Time to PSA recurrence was compared between users and nonusers of statin at surgery using Cox proportional hazards models adjusted for multiple clinical and pathological features.

RESULTS: In total, 236 (18%) men were taking statins at RP. Median follow-up was 24 months for statin users and 38 for nonusers. Statin users were older (Psimvastatin 20 mg: HR, 0.50; 95% CI, 0.27-0.93; P=.03).

CONCLUSIONS: In this cohort of men undergoing RP, statin use was associated with a dose-dependent reduction in the risk of biochemical recurrence. If confirmed in other studies, these findings suggest statins may slow PC progression after RP.

Author-supplied keywords

  • Hydroxymethylglutaryl-coenzyme A reductase inhibitors
  • Prostate neoplasms
  • Radical prostatectomy
  • Statins

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free